MRGBP

Across TCGA pan-cancer cohorts, MRGBP mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MRGBP data layer compared with 30 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher MRGBP mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated MRGBP expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

LUAD, PDAC, and GBM are the cancer types where MRGBP mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	All	1.000	0.910	.014	9	view →
PDAC	OS	Median	All	0.648	0.463	.007	6	view →
GBM	OS	Median	All	0.599	0.448	.041	3	view →
HNSC	OS	Quartile	II,III,IV	0.861	0.958	.030	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MRGBP–LUAD (OS)

Open the LUAD breakdown →